Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
16 pending office actions • 10 art units • 16 examiners • 0 of 16 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
National University Corporation Kobe University has 15 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 15 examiners and 9 art units, showing broad distribution across the biotechnology and pharmaceutical examination groups.
FAIRCHILD, MALLIKA DIPAYAN is the busiest examiner, with 1 pending matter. No examiner carries a large concentration of the pending workload, so a uniform prosecution strategy may be less useful than matter-specific preparation.
The difference between examiner and art-unit coverage also matters operationally. Multiple examiners are working within some art units, while the total set of actions remains distributed among the available technical assignments. Counsel should track office-action themes by examiner and art unit, preserve matter-level distinctions, and avoid assuming that an argument effective in one application will receive the same treatment elsewhere.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (12%) |
| §103 only | 1 (6%) |
| §112 only | 2 (12%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 3 (19%) |
| Multi-statute (no §101) | 7 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAIRCHILD, MALLIKA DIPAYAN | 1 | 79.5% | +18.2% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| KUBELIK, ANNE R | 1 | 75.8% | -1.1% |
| KWAK, DEAN P | 1 | 58.8% | +37.1% |
| NOAKES, SUZANNE MARIE | 1 | 73.4% | +18.3% |
| FERRE, ALEXANDRE F | 1 | 59.1% | +20.1% |
| NGUYEN, HENRY H | 1 | 63.5% | +36.7% |
| WARD, AARON DUREL | 1 | 0.0% | +0.0% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
| CHONG, KIMBERLY | 1 | 72.3% | +13.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687023 | CORE-SHELL TEMPLATE MOLECULE/PARTICLE FOR TECHNIQUE FOR HIGH-YIELD FORMATION OF PORES ON SUBSTRATE | FERRE, ALEXANDRE F | 7d |
| 18868907 | ORAL MUSCLE TRAINING INSTRUMENT AND ORAL MUSCLE TRAINING METHOD | FAIRCHILD, MALLIKA DIPAYAN | — |
| 18292565 | RAS/RAF BINDING INHIBITOR COMPOUND | MOORE, SUSANNA | — |
| 18741424 | METHOD FOR SELECTING PROMOTER THAT FUNCTIONS IN ORGANELLE | KUBELIK, ANNE R | — |
| 18702815 | ARTIFICIAL BIOMEMBRANE CONTAINING MEMBRANE PROTEIN | KWAK, DEAN P | — |
| 18687012 | TECHNIQUE FOR ALIGNING PARTICLES ON SUBSTRATE WITHOUT AGGLOMERATION | NGUYEN, HENRY H | — |
| 18577111 | NEPHROTOXICITY REDUCING AGENT | WARD, AARON DUREL | — |
| 18550777 | CANCER THERAPY | CHONG, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634640 | COMPLEX FOR GENOME EDITING HAVING STABILITY AND FEW SIDE-EFFECTS, AND NUCLEIC ACID CODING SAME | NOAKES, SUZANNE MARIE | 7d |
| 18687023 | CORE-SHELL TEMPLATE MOLECULE/PARTICLE FOR TECHNIQUE FOR HIGH-YIELD FORMATION OF PORES ON SUBSTRATE | FERRE, ALEXANDRE F | 7d |
| 18539833 | METHOD FOR CONVERTING NUCLEIC ACID SEQUENCE OF CELL SPECIFICALLY CONVERTING NUCLEIC ACID BASE OF TARGETED DNA USING CELL ENDOGENOUS DNA MODIFYING ENZYME, AND MOLECULAR COMPLEX USED THEREIN | STEADMAN, DAVID J | 71d |
| 18868907 | ORAL MUSCLE TRAINING INSTRUMENT AND ORAL MUSCLE TRAINING METHOD | FAIRCHILD, MALLIKA DIPAYAN | — |
| 18292565 | RAS/RAF BINDING INHIBITOR COMPOUND | MOORE, SUSANNA | — |
| 18702815 | ARTIFICIAL BIOMEMBRANE CONTAINING MEMBRANE PROTEIN | KWAK, DEAN P | — |
| 18687012 | TECHNIQUE FOR ALIGNING PARTICLES ON SUBSTRATE WITHOUT AGGLOMERATION | NGUYEN, HENRY H | — |
| 18550777 | CANCER THERAPY | CHONG, KIMBERLY | — |
| Art Unit | Apps |
|---|---|
| 1636 | 4 |
| 1663 | 2 |
| 1656 | 2 |
| 3792 | 1 |
| 1624 | 1 |
| 1795 | 1 |
| 1788 | 1 |
| 1637 | 1 |
| 1633 | 1 |
| 1764 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18868907 | ORAL MUSCLE TRAINING INSTRUMENT AND ORAL MUSCLE TRAINING METHOD | FAIRCHILD, MALLIKA DIPAYAN | 3792 | §101§102§103 | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18292565 | RAS/RAF BINDING INHIBITOR COMPOUND | MOORE, SUSANNA | 1624 | §102§103§112 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18741424 | METHOD FOR SELECTING PROMOTER THAT FUNCTIONS IN ORGANELLE | KUBELIK, ANNE R | 1663 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18702815 | ARTIFICIAL BIOMEMBRANE CONTAINING MEMBRANE PROTEIN | KWAK, DEAN P | 1795 | §102§112Other | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18634640 | COMPLEX FOR GENOME EDITING HAVING STABILITY AND FEW SIDE-EFFECTS, AND NUCLEIC ACID CODING SAME | NOAKES, SUZANNE MARIE | 1656 | DP | Final Rejection | 7d | Pending | Apr 12, 2024 |
| 18687023 | CORE-SHELL TEMPLATE MOLECULE/PARTICLE FOR TECHNIQUE FOR HIGH-YIELD FORMATION OF PORES ON SUBSTRATE | FERRE, ALEXANDRE F | 1788 | §102§112 | Final Rejection | 7d | Pending | Feb 27, 2024 |
| 18687012 | TECHNIQUE FOR ALIGNING PARTICLES ON SUBSTRATE WITHOUT AGGLOMERATION | NGUYEN, HENRY H | — | §102§112Other | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18577111 | NEPHROTOXICITY REDUCING AGENT | WARD, AARON DUREL | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18539833 | METHOD FOR CONVERTING NUCLEIC ACID SEQUENCE OF CELL SPECIFICALLY CONVERTING NUCLEIC ACID BASE OF TARGETED DNA USING CELL ENDOGENOUS DNA MODIFYING ENZYME, AND MOLECULAR COMPLEX USED THEREIN | STEADMAN, DAVID J | 1656 | §112 | Final Rejection | 71d | Pending | Dec 14, 2023 |
| 18550777 | CANCER THERAPY | CHONG, KIMBERLY | 1636 | §102§112 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18548008 | SEMI-RATIONAL GENOME EVOLUTION ENGINEERING METHOD FOR PLANTS | STOCKDALE, JESSICA NICOLE | 1663 | §102§103Other | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18278498 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | ZAHORIK, AMANDA MARY | 1636 | §103 | Final Rejection | 27d | Pending | Aug 23, 2023 |
| 18259831 | GENE FUNCTION CONTROL BY NOVEL GUIDE NUCLEIC ACID MECHANISM | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§112 | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18044047 | MINIATURIZED CYTIDINE DEAMINASE-CONTAINING COMPLEX FOR MODIFYING DOUBLE-STRANDED DNA | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §112 | Non-Final OA | 26d | Pending | Mar 03, 2023 |
| 18151212 | MANUFACTURING METHOD FOR HOLLOW FINE PARTICLES, AND HOLLOW FINE PARTICLES | KRYLOVA, IRINA | 1764 | §103DP | Final Rejection | 82d | Pending | Jan 06, 2023 |
| 16838960 | GENOMIC SEQUENCE MODIFICATION METHOD FOR SPECIFICALLY CONVERTING NUCLEIC ACID BASES OF TARGETED DNA SEQUENCE, AND MOLECULAR COMPLEX FOR USE IN SAME | SU-TOBON, QIWEN NMN | 1636 | §103§112DP | Final Rejection | 89d overdue | Pending | Apr 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNational University Corporation Kobe University has 16 pending office actions as of October 2026, spread across 10 art units and 16 examiners.
Mallika Dipayan Fairchild has the most, with 1 of National University Corporation Kobe University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
